Biotech Short Candidates Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (620)	12/3/2003 7:28:08 PM
From: Miljenko Zuanic	of 897

Peter, VHL-HIF correlation and connection can explain tumor activity from ati-angiogenic agents. Will this approach bring survival and disease progression free benefit we do not know. Avastin did have encouraging small PII results. I am simple pointing that 12 weeks response rate (with reduced tolerance) is too early to translate into successful PIII. Update at ASCO-2004 will be very important, and at that time we may know does ONXX has winner, or another failure. Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next